Developing the future of CAR-T cell therapy today
Novartis is pioneering the way in the class of cell and gene treatment and has developed the first CAR-T cell therapy approved for paediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). This heritage includes setting the standard in patient and caregiver support, safety and efficacy, access, and partnerships with healthcare institutions, local health authorities, and academic institutions around the world.